Want to see LYEL full AI Analyst Report?
Lyell Immunopharma (LYEL) Stock Statistics & Valuation Metrics
Total Valuation
Lyell Immunopharma has a market cap or net worth of $270.54M. The enterprise value is $170.76M.
- Market Cap
- $270.54M
- Enterprise Value
- $170.76M
Share Statistics
Lyell Immunopharma has 24,505,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 24,505,140
- Owned by Insiders
- 39.34%
- Owned by Institutions
- 13.93%
Financial Efficiency
Lyell Immunopharma’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -67.99%.
- Return on Equity (ROE)
- -1.11
- Return on Assets (ROA)
- -0.81
- Return on Invested Capital (ROIC)
- -67.99%
- Return on Capital Employed (ROCE)
- -0.70
- Revenue Per Employee
- 223.602
- Profits Per Employee
- -1.70M
- Employee Count
- 161
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lyell Immunopharma is -0.69. Lyell Immunopharma’s PEG ratio is 0.01.
- PE Ratio
- -0.69
- PS Ratio
- 10019.86
- PB Ratio
- 1.10
- Price to FCF
- -2.02
- Price to Operating Cash Flow
- -1.94
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 36.00K and earned -274.45M in profits. Earnings per share was -16.06.
- Revenue
- 36.00K
- Gross Profit
- -11.50M
- Operating Income
- -203.77M
- Pretax Income
- -274.45M
- Net Income
- -274.45M
- EBITDA
- -262.91M
- Earnings Per Share (EPS)
- -16.06
Cash Flow
In the last 12 months, operating cash flow was -133.26M and capital expenditures -711,000, giving a free cash flow of -133.97M billion.
- Operating Cash Flow
- -133.26M
- Free Cash Flow
- -133.97M
- Free Cash Flow per Share
- -5.73
Dividends & Yields
Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -49.52%
- Earnings Yield
- -96.33%
Stock Price Statistics
- Beta
- 1.71
- 52-Week Price Change
- -33.21%
- 50-Day Moving Average
- 11.00
- 200-Day Moving Average
- 16.77
- Relative Strength Index (RSI)
- 61.45
- Average Volume (3m)
- 151.12K
Important Dates
Lyell Immunopharma upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Lyell Immunopharma as a current ratio of 5.28, with Debt / Equity ratio of 20.55%
- Current Ratio
- 5.28
- Quick Ratio
- 5.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.03
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lyell Immunopharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lyell Immunopharma EV to EBITDA ratio is -0.98, with an EV/FCF ratio of -1.75.
- EV to Sales
- 8684.64
- EV to EBITDA
- -0.98
- EV to Free Cash Flow
- -1.75
- EV to Operating Cash Flow
- -1.76
Balance Sheet
Lyell Immunopharma has $204.10M in cash and marketable securities with $36.93M in debt, giving a net cash position of $167.17M billion.
- Cash & Marketable Securities
- $204.10M
- Total Debt
- $36.93M
- Net Cash
- $167.17M
- Net Cash Per Share
- $6.82
- Tangible Book Value Per Share
- $10.01
Margins
Gross margin is -8537.04%, with operating margin of -711329.63%, and net profit margin of -920285.19%.
- Gross Margin
- -8537.04%
- Operating Margin
- -711329.63%
- Pretax Margin
- -920285.19%
- Net Profit Margin
- -920285.19%
- EBITDA Margin
- -885037.04%
- EBIT Margin
- -920285.19%
Analyst Forecast
The average price target for Lyell Immunopharma is $36.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $36.20
- Price Target Upside
- 227.90% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -55.00%
- EPS Growth Forecast
- 51.58%
Scores
- Smart Score
- 5
- AI Score
- 48
